Vigabatrin administration for infants and young children with intractable generalized epilepsy

Area of Science:

• Pediatric Neurology
• Epileptology
• Pharmacology

Background:

• Intractable generalized epilepsy in infants and young children presents significant treatment challenges.
• Drug-resistant epilepsy often requires exploring various antiepileptic drug (AED) options.
• Vigabatrin (VGB) is an AED sometimes considered for difficult-to-treat epilepsy syndromes.

Purpose of the Study:

• To evaluate the real-world effectiveness of vigabatrin (VGB) in pediatric patients with intractable generalized epilepsy.
• To identify specific epilepsy types or conditions where VGB might be beneficial.
• To assess the outcomes of VGB treatment in a cohort of infants and young children.

Main Methods:

• Retrospective analysis of 12 pediatric patients treated with VGB.
• Inclusion criteria: infants and young children with intractable generalized epilepsy.
• Data collected on epilepsy type, prior AEDs, and VGB response.

Main Results:

• The study included patients with West syndrome, early-infantile epileptic encephalopathy, and other generalized epilepsy types.
• All patients had drug-resistant epilepsy, having failed a median of 5 prior AEDs.
• VGB demonstrated effectiveness in only one case of symptomatic West syndrome associated with tuberous sclerosis; transient effects were noted in two other West syndrome cases.

Conclusions:

• Vigabatrin (VGB) exhibits poor overall effectiveness for intractable generalized epilepsy in infants and young children.
• The exception appears to be West syndrome associated with tuberous sclerosis, where VGB may be beneficial.
• Clinical decision-making for VGB administration requires careful case selection and consideration of potential limited efficacy.